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Cost-Effectiveness of a Smoking Cessation Program
Implemented at the Time of Surgery for Lung Cancer
Christopher G. Slatore, MD, MS,*† David H. Au, MD, MS,*† and William Hollingworth, PhD‡
Background: Many patients are active smokers at the time of a
diagnosis of surgically resectable lung cancer. Perioperative smok-
ing cessation is associated with improved survival, but the cost-
effectiveness of a smoking cessation program initiated immediately
before surgery is unknown.
Methods: We developed a decision analytic Markov model to
evaluate the incremental cost-effectiveness of a formal smoking
cessation program. The parameter estimates were taken from the
available literature. The model included the cost and effectiveness of
the smoking cessation program, cost and incidence of perioperative
complications, postoperative mortality, and utility measured in qual-
ity adjusted life years (QALY). Dollars per QALY and life year
were calculated and one-way sensitivity analyses were performed.
Results: The cost/QALY and cost/life year were $16,415 and
$45,629 at 1 year after surgery and $2609 and $2703 at 5 years,
respectively. Most sensitivity analyses showed the 1 year postsur-
gery cost/QALY estimates were less than $50,000, and all were less
than $12,000 at 5 years. Cost-effectiveness estimates were most
sensitive to the frequency of perioperative complications and the
estimated short-term utility estimates.
Conclusion: A smoking cessation program initiated before surgical
lung resection is cost-effective at both 1 and 5 years postsurgery.
Providers should encourage patients who are still smoking to engage
in formal smoking cessation programs.
Key Words: Cost-effectiveness, QALY, Smoking cessation pro-
gram, Non-small cell lung cancer.
(J Thorac Oncol. 2009;4: 499–504)
Lung cancer is the second most common cancer among menand women in the United States and the leading cause of
cancer-related mortality1 with 90% of all lung cancer diag-
noses attributable to smoking tobacco.2 Smoking cessation
decreases the risk of lung cancer3 and interventions to induce
abstinence have been found to reduce lung cancer incidence
and mortality.4,5 In addition, smoking cessation programs are
cost-effective by most standards; for example, a study of the
Agency for Health Care Policy and Research smoking ces-
sation program guidelines showed an incremental cost-effec-
tiveness of $1915 per quality adjusted life year (QALY) at 1
year after the intervention.6
Approximately 20% of patients actively smoke at the
time of lung cancer surgery and 30 to 60% of these patients
continue to smoke afterward.7,8 Cessation shortly before
surgery for lung cancer is associated with improved long-
term survival.9 Discussing or receiving a diagnosis of a
smoking-related illness is not associated with abstinence.10
However, lung cancer surgery may be a “teachable moment”
and cessation programs at the time of surgery for patients
without lung cancer are effective.11–15 Limited evidence sug-
gests smoking cessation programs may be effective for pa-
tients with lung cancer16,17 and are recommended.18
Expected 5-year survival for non-small cell lung cancer
(NSCLC) is 60 to 75% for stage I and 36 to 60% for stage II
disease.1 This survival time is likely long enough for patients
to enjoy quality of life improvements from abstinence.19 No
study has evaluated a smoking cessation intervention for
patients referred for surgical management of lung cancer.20
We used the available evidence to develop a decision analysis
model to evaluate the cost-effectiveness of a smoking cessa-
tion intervention initiated preoperatively for patients with
NSCLC.
PATIENTS AND METHODS
We developed a decision analytic Markov model to
evaluate the incremental cost-effectiveness of a smoking
cessation program initiated before surgical resection for pa-
tients with NSCLC at stage IIIB or less compared with
patients not offered a program (usual care). The decision tree,
describing perioperative outcomes and 1-year survival, is
shown (Figure 1) with probabilities, utility, and costs of the
model in Table 1. We included costs from the perspective of
health care providers. The model was analyzed in Microsoft
Excel SP2003 (Redmond, WA).
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Effectiveness of Smoking Cessation Program
Preoperative smoking cessation programs have been
studied in heterogeneous settings11–14 so an overall effective-
ness estimate is not available15. We used an estimate based on
a similar setting to ours, using a program of counseling and
nicotine replacement.11 Seventy-eight percent of smokers in
the treatment arm were abstinent at the time of surgery
compared with 65% of usual care patients; 3 months post-
surgery, the abstinence rate was 19% compared with 12% of
patients in usual care. Long-term abstinence likely underlies
some of the mechanism for improved survival for those who
quit before surgery21 and provides a more conservative esti-
mate in this case. Thus, we chose these latter parameters for
estimating long-term mortality but use the rates at the time of
surgery for the perioperative complication estimates. All
studies showed an improvement in abstinence rates with a
formal program so a 5 percentage point improvement was
used as the minimal difference for the sensitivity analysis.
Cost of Smoking Cessation Program
The program includes nicotine replacement with two
short (Centers for Medicare & Medicaid Services [CMS]
Current Procedural Terminology code 99401) and two long
(99402) sessions; average reimbursement is $13 and $25 for
codes 99401 and 99402, respectively.22,23 We test program
costs in a sensitivity analysis that include costs of bupropion
or varenicline therapy.24
Perioperative Pulmonary Complications
Probabilities
Most studies have not shown a differential rate of
perioperative complications.11,12,25,26 Recent quitters (2
months of abstinence) and current smokers both had a 23%
incidence of perioperative complications after thoracotomy
for lung cancer.26 An oft-quoted study found 33% of current
smokers had perioperative pulmonary complications com-
pared with 57% for recent quitters (8 weeks of absti-
nence).27 Thus, we used a 23% rate of complications for both
groups in the primary analysis, increasing the complication
rate up to 40 percentage points higher for recent quitters in a
sensitivity analysis.
Perioperative Pulmonary Complication Costs
CMS does not pay for complications after lobectomy
or pneumonectomy except when the case becomes a cost
outlier.28 However, perioperative pulmonary complications
are associated with a 73% increase in direct costs,29 leading
to an estimated total cost of $30,896 based on average CMS
reimbursement.30
Mortality
Current smokers at the time of resection for NSCLC of
stage IIIB or less had a median survival of 43 months.9 In
comparison, 77% of recent quitters (3 months to 1 week
before surgery) were alive at 5 years. The sensitivity analysis
reflects the upper 95% confidence interval for the smallest
FIGURE 1. It shows the decision tree developed from the available evidence. Patients diagnosed with resectable stage IIIB or
less non-small cell lung cancer are offered a smoking cessation program or usual care. Each number represents the probability
of progressing to one stage or the other. Periop, perioperative.
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difference in mortality rates between continued smokers and
recent quitters.9
Health-Related Quality of Life
The mean health-related quality of life (HRQOL) utility
score postsurgery is 0.59 for patients with operable NSCLC.31
Thirty-two percent were current smokers, but the utility
score was not stratified by smoking status. Therefore, we
used a second study of lung cancer survivors to approxi-
mate utility scores by smoking status although we could
not directly convert the HRQOL score to a QALY.8 The
score was 28.7 for current smokers compared with 22.1 for
former smokers. In our base case analysis, we used this
crude 77% (22.1/28.7) adjustment to the utility score
(0.59), and the proportion of smokers and nonsmokers, to
estimate utility scores for current smokers (0.49) and recent
quitters (0.64).
Recent quitters may have decreased HRQOL early after
cessation32 although this difference is reversed at 1 year.19
We use 1-year utility gains from quitting in our base case but
use a short-term decreased QALY for quitters (based on
converting SF-36 scores to QALYs33) in sensitivity analyses.
Markov Analysis
Three states after resection were possible: alive smok-
ers, alive nonsmokers, or dead. To convert 5-year mortality
rates9 to annual transition probabilities (tp1) between states
for the Markov model we used the formula: tp1  1  (1 
tp5)
1/5. The annual probability of mortality for recent quitters
and current smokers is 5.1% and 17.6%, respectively (Table
2). We assumed that any deaths during a year occurred on
average half way through the year (i.e., half cycle correction)
and used a discount rate of 3% per year for outcomes after the
first year.
Sensitivity Analyses
One-way sensitivity analyses of cost-effectiveness at 1
and 5 years postsurgery were performed for the postoperative
complication rate, the cost of the intervention, effectiveness
of the intervention, mortality difference between current
smokers and recent quitters, and difference in utility scores
(Table 1). We use a cost per QALY of $50,000 as a threshold
value.34
RESULTS
One year after surgery the smoking cessation program
group had 0.48 QALYs compared with 0.47 QALYs for the
usual treatment group (Table 3). Subjects assigned to a
smoking cessation program had 0.924 life years compared
with 0.920 life years for the group in usual care. These
differences equate to a cost/QALY of $16,415 and a cost/life
year of $45,629. The Markov analysis shows that the cumu-
lative life years and QALYs continue to separate over time
(Table 3). For example, there was a difference of 0.09
QALYs and 0.08 life years at 5 years postsurgery. These
differences equate to a cost/QALY of $2609 and a cost/life
year of $2703.
If perioperative complications occur at a differential
rate of 33% for continued smokers and 57% for recent
quitters (as in Warner et al.27), the cost/QALY was $49,945
and the cost/life year was $138,835 at 1 year postsurgery. At
5 years, these estimates yielded a cost/QALY of $7938 and a
cost/life year of $8224. Figure 2 shows how cost/QALY and
cost/life year at 5 years postsurgery is affected as the differ-
ential perioperative complication rate in subjects who are
recent quitters increases. At 1-year postsurgery, the threshold
value (cost/QALY of $50,000) occurred if recent quitters had
a differential rate of perioperative complications 24 percent-
age points higher than smokers, with no threshold at 5 years.
TABLE 2. Markov Transition Probabilities (yr 2–5)
Start of Year
End of Year
Smoker Nonsmoker Dead
Smoker 0.824 0 0.176
Nonsmoker 0 0.949 0.051
Dead 0 0 1
TABLE 1. Parameter Estimates
Parameter Base Case (Range) References
Smoking cessation program
costs
Cost per visit 19, 20
99401 (G0375) $13
99402 (G0376) $25
Nicotine patches (8 wk
supply)
$123.96 21
Total $199.96 ($50–$450)a
Smoking cessation program
effectiveness
Program abstinence rate 3
mo postsurgeryb
19% (12–62%) 11
Usual care abstinence rate 3
mo postsurgeryb
12% 11
Program abstinence rate at
time of surgeryc
78% 11
Usual care abstinence rate
at time of surgeryc
65% 11
Perioperative complications
Recent quitters 23% (23–63%) 23, 24
Current smokers 23% 23, 24
Surgical costs
No complications $17,859 27
Perioperative pulmonary
complications
$30,896 26
Yearly mortality
Recent quitters 5.1% 9
Current smokers 17.6% (10–55%) 9
Utility scores
Recent quitters 0.64 (0.47–0.99) 8, 28, 29
Current smokers 0.49 8, 28, 29
a Range includes cost of bupropion or varenicline.
b Used for mortality estimates of program compared with usual care participants.
c Used for perioperative complication estimates of program compared with usual
care participants.
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At the upper limit of $450 for the smoking cessation
program, the cost/QALY and cost/life year at 5 years postint-
ervention were $5871 and $6083, respectively (Figure 3). At
both 1 and 5 years postsurgery, the threshold value of cost-
effectiveness was not reached.
At 1 year assuming an increase of 5 percentage points
for smokers achieving abstinence at 3 months with the pro-
gram, the cost/QALY and cost/life year were $22,981 and
$63,881, respectively. At 5 years, these estimates are $3652
and $3784, respectively. Figure 4 shows how cost-effective-
ness changes as the effectiveness of the program at inducing
abstinence at 3 months postsurgery increases over usual care.
At both 1 and 5 years postsurgery, the threshold value of
cost-effectiveness was not reached.
At 1 year postsurgery with a 5 percentage point in-
creased mortality for continued smokers compared with re-
cent quitters, that is, a mortality rate of 10.1% for continued
smokers, the cost/QALY, and cost/life year were $18,368 and
$114,263 respectively. At 5 years postsurgery, this differen-
tial rate of mortality translated to a cost/QALY of $3560 and
FIGURE 2. It shows the 5-year postsurgery differences in
cost/quality adjusted life years (QALY) and cost/life year as
the proportion of recent quitters who suffer perioperative
complications increases over the rate of continued smokers
with perioperative complications. Note that the base case
assumes no difference in the proportions suffering periopera-
tive complications.
FIGURE 3. It shows the 5-year postsurgery differences in
cost/quality adjusted life years (QALY) and cost/life year as
the cost of the smoking cessation program changes. Note
that the base case has a cost of approximately $200.
FIGURE 4. It shows the 5-year postsurgery differences in
cost/quality adjusted life years (QALY) and cost/life year as
the effectiveness of the smoking cessation program changes.
Note that the base case assumes the smoking cessation pro-
gram leads to an increase of 7% of the subjects achieving
abstinence at 3 months postsurgery.
FIGURE 5. It shows the 5-year postsurgery differences in
cost/quality adjusted life years (QALY) and cost/life year as
the proportion of smokers who are deceased at 1 year after
surgery increases over the proportion of recent quitters who
are deceased. Note that the base case assumes that smokers
have a 12% higher proportion who are deceased at 1 year
compared with recent quitters.
TABLE 3. Markov Analysis for Cumulative QALY’s and Life Years and Costs Effectiveness by Year
After Surgery
Yeara
Program Usual Care
Cost/QALYb Cost/life YearbQALYs Life Years QALYs Life Years
1 0.48 0.924 0.47 0.920 $16,415 $45,629
2 0.89 1.71 0.87 1.69 $7,441 $12,455
3 1.25 2.38 1.20 2.34 $4,649 $6,120
4 1.55 2.95 1.49 2.89 $3,344 $3,813
5 1.82 3.44 1.73 3.36 $2,609 $2,703
a Utilizes half cycle correction.
b Includes 3% discount/yr.
QALY, quality adjusted life years.
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a cost/life year of $6182 with the ranges shown in Figure 5.
At both 1 and 5 years postsurgery, the threshold value of
cost-effectiveness was not reached.
At 1 year postsurgery if recent quitters had a utility
estimate of 0.02 less than smokers, the program was associ-
ated with a cost/QALY of $252,567. At 5 years postsurgery,
this lower utility adjustment for quitters had a cost/QALY of
$6467 with the ranges shown in Figure 6. At 1 year postsur-
gery the cost-effectiveness occurred at a threshold of quitters
having a utility score 0.03 higher than smokers and did not
occur for any estimate of utility at 5 years postsurgery.
DISCUSSION
Cost-effectiveness of a smoking cessation intervention
at 5 years after surgery was estimated to be $2609 per QALY
and was less than $12,000 per QALY under most assump-
tions tested in the sensitivity analyses. These estimates are
sensitive to changes in the differential rate of perioperative
pulmonary complications based on smoking status. Five
years after surgery, the one-way sensitivity analyses of the
cost of the program, effectiveness of the program, mortality
difference between continued smokers and recent quitters,
and utility difference between smokers and quitters are all
consistent with cost-effectiveness estimates of less than
$7000 per QALY and life year. In comparison, it has been
estimated to cost $47,676 per QALY to pursue annual com-
puted tomography surveillance for recurrence after resection
for stage IA NSCLC.35
Many patients actively smoke at the time of a diagnosis
of lung cancer7 and there may be pessimism by both patients
and clinicians regarding the value of abstinence. However,
tobacco cessation even at this late stage is associated with
both decreased mortality and increased quality of life.8,9 Our
results indicate that at 5 years after surgery, the cost-effec-
tiveness of a smoking cessation program is likely below the
commonly used threshold of $50,000/QALY.36 The results 1
year after surgery are similar although more affected by the
utility and perioperative complication estimates.
Cost-effectiveness analyses using decision analytic
models developed from the available evidence are limited by
the availability, quality, and generalizability of data to inform
the model. Several studies have explored the prognostic value
of preoperative smoking status with mortality after lung
cancer resection.37–40 Only one observational study evaluates
the association of short-term preoperative smoking cessation
on subsequent mortality, and this study did not evaluate
stage-specific survival.9 However, there was no stage and
smoking status interaction observed in this analysis so the
overall difference in mortality is likely the same for recent
quitters and continued smokers with the same stage of dis-
ease. Smoking status at the time of chemotherapy is associ-
ated with its effectiveness,21 but no data are available on
postoperative recidivism rates to guide inclusion of this
aspect in the model. The sensitivity analysis of mortality
differences for smokers and recent quitters shows that a
smoking cessation program is likely cost-effective even with
minimal differences in mortality.
The QALY estimates are limited by the available evi-
dence. The only study that examined the differences in utility
associated with smoking status in lung cancer survivors used
a measure that cannot be translated into a QALY.8 Smoking
cessation is associated with increased utility at 1 year19 at the
expense of a decrease in short-term utility,32 and it is unclear
when this decrement is reversed. Thus, our results may
overestimate cost-effectiveness for patients who die shortly
after surgery. In addition, quality of life is affected by stage
of disease31 but there was no information how this differs by
smoking status. However, if quitters have a better quality of
life than current smokers regardless of stage, our results are
still applicable. Overall, the sensitivity analysis shows a
program is likely cost-effective over a broad range of utility
estimates.
Our Markov analysis examined three postoperative
states, alive-smoker, alive-nonsmoker, or dead, but there are
certainly gradations of quality of life. It may be that recent
quitters have fewer recurrences, in which case our analysis is
conservative. Alternatively, those who would have died had
they not quit, might have a poor quality of life if they develop
metastases and other complications.
We did not include costs of treating recurrent or met-
astatic disease. The lower mortality in recent quitters9 might
be due to lower rates of recurrence and metastases. A smok-
ing cessation program would probably be more cost-effective
once the costs of treating these disease stages are included.
However, if recent quitters are less likely to die, but live longer
with recurrent or metastatic disease, we would overestimate the
cost-effectiveness of the cessation program. We did not include
costs and effects of treating other smoking-related diseases
which presumably would decrease the cost/QALY.
Despite the conflicting data on the timing of smoking
cessation and perioperative pulmonary complications, there is
no evidence of increased mortality for recent quitters.25–27
Perioperative complications lower quality of life, but there
are no data to guide estimates of utility. In addition, because
our utility estimates are derived from cohorts of patients who
likely suffered perioperative complications, our results incor-
porate short-term quality of life decrements. However, simi-
lar to our overall estimate of QALYs, our results overestimate
the cost-effectiveness for patients who survive a short period
of time after surgery.
FIGURE 6. It shows the 5-year postsurgery differences in
cost/quality adjusted life years (QALY) as the utility of smok-
ers changes with respect to quitters. Note that the base case
assumes that quitters have a utility score 0.15 higher than
smokers.
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Our results are not applicable to lung cancer patients
with inoperable disease. The results may be less relevant to
patients who are expected to survive a short time after surgery
although even the 1-year cost-effectiveness estimates are
below $50,000 per QALY. Individual patients may be able to
quit smoking without assistance so a formal cessation pro-
gram may not offer incremental benefit.
Smoking cessation is beneficial in most situations, even
for those who have already been diagnosed with operable
lung cancer. Our results show a smoking cessation program is
likely to be cost-effective over a broad range of underlying
assumptions about mortality, utility, and program effective-
ness. We suggest that smokers undergoing evaluation for
lung cancer should participate in smoking cessation programs
and health care payers cover the expenses.
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